Please type a plus sign (+) i		×		U.S. Pater	nt and Trademark Off	ice, U.S. Di	EPARTMEN	NT OF COMME	RCE	
Under the Paperwork Reduction		persons are required to a						MB COINTOI BOT	iber.	
UTILITY						C 84,63			-	
PATENT APPLICATION				First Inventor Swider-Lyons						
ITA	TRANSMITTAL				DROUS PHOSPHAT	E CATALY	STS WITH	I LOW PLATIN	UM	
(Only for new non provisional applications under 37 CFR 1.53(b))				Express Mail Label No.						
APPLICA	TION ELEN	MENTS		ADD	RESS TO: BG	Assistant (	Commission Applicati	oner for Paten	its	
See MPEP chapter 600 conc			nts.			Washingto	on, DC 20	231		
Fee Transmittal Fe (Submit an original and	orm (e.g., P10 d a distilicate for fee pro	/SB/17) cessing)		7.	CD-ROM or CD- Computer Progra			e table or	_	
2. Applicant claims s See 37 CFR 1.27.	mall entity stat			8. Nucl	eotide and/or Amin	no Acid Se		ubmission	PT0	
Specification	[Total	Pages 12		(if applicable, all necessary)  a. Computer Readable Form (CRF)						
- Descriptive title	of the invention			b. Specification Sequence Listing on:						
- Cross Referenc	e to Related Ap	pplications								
- Reference to se	equence listing,	, a table,		CD-ROM or CD-R (2 copies); or						
or a computer p - Background of	the Invention			c. Statements verifying identity of above copies						
- Brief Summary	of the Invention			ACCOMPANYING APPLICATION PARTS						
Brief Description of the Drawings (if filed)     Detailed Description				9.	Assignment Pa					
- Claim(s) - Abstract of the Disclosure				10. 37 CFR 3.73(b) Statement Power of Attorney						
4, X Drawing(s) (35 U. S. C. 113) [ Total Sheets 8				11.	English Transl			applicable)		
5. Oath or Declaration   Total Pages   20				12.	Information Dis	sclosure		Copies of I	DS	
			٠ د	13.	Statement (IDS Preliminary Art			_ J		
a. Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed)				14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)				15.	Certified Copy			nt(s)		
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).				16.	Request and ( (b)(2)(13)(i). A	Certificatio	on under 3	5 U.S.C. 122	1/35	
6. Application Data Sheet. See 37 CFR 1.76				or its equivalent.						
	17.	Other:								
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1, 76:										
Continuation Ovisional Continuation-in-part (CIP)					of prior application No.:					
Prior application information: Examiner Group Art Unit.									1-0	
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.										
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.  19 CORRESPONDENCE ADDRESS										
X Customer Number or Bar Code Label (Insert Customer Place As				ar code label here) or Correspondence address below						
Name	Mayal Rese	CUSTOMER	NTIMBED		<u> </u>					
Name	Name Naval Research Laboratory, Code 1008.2  4555 Overlook Ave., S.W.									
Address										
City	Code 1008.2 Washington			State DC		Z	ip Code	20375-532	:0	
Country	·			hone 202-404-1552			Fax	202-404-7	380	
Name (Print/Type)	L							82	=	
Ivanie (Filito Type)	JOHN J. IXIII	1301		1,109	Direction (Filter	1	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	<del></del>		

Signature

Burton How Statement: This Javem's estimatiff to take 0.2-Motirs to complete. Timp.wiff vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this firm about be sent justific those individual case. Any comments on a mount of time you are required to complete this firm about be sent justific those individual case. U. S. Patient and Trademark Office, Washington, DC 2023.1. ON NOT SEND FEES OR COMPLETED FORMS TO THIS ATDRESS. SEND TO: Assistant Commissioner for Patients, Box Patient Application, Washington, DC 20231.

09/26/

PTO/SB/17 (01-03)
Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995, no Parsons are required to respond to a collection of information unless it displays a valid OMB control number
Complete if Known

## FEE TRANSMITTAL Application Number Not vet assigned for FY 2003 Filing Date September 26, 2003 First Named Inventor Swider-Lyons Effective 0110112003. Patent fees are subject to annual revision **Evaminer Name** Not vet assigned Applicant claims small entity status. See 37 CFR 1.27 Art Unit Not vet assigned TOTAL AMOUNT OF PAYMENT (\$) 768 Attorney Docket No. 84.631 METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued) Money 3. ADDITIONAL FEES Check Credit card Other Mono Large Entity , Small Entity Deposit Account Fee Fee Fee Fee Fee Description Denocit Code (\$) ee Paid Account 50-0281 1051 130 2051 65 Surcharge - late filing fee or oath Number Deposit 1052 50 2052 25 Surcharge - late provisional filing fee or NAVAL RESEARCH LABORATORY cover cheet 1053 130 1053 130 Non-English specification Commissioner is authorized to: (check all that apply) 1812 2 520 1812 2,520 For filing a request for ex parte reexamination Charge fee(s) indicated below Credit any overpayments 1804 920° 1804 920\* Requesting publication of SIR prior to Examiner action Charge any additional fee(s) during the pendency of this application charge fee(s) indicated below, except for the filing fee 1805 1.840\* 1805 1.840\* Requesting publication of SIR after ahovo-identified denosit account 1251 110 2251 55 Extension for reply within first month FEE CALCULATION 1252 410 2252 205 Extension for reply within second month 1. BASIC FILING FFF 1252 930 2253 465 Extension for reply within third month arge Entity Small Entity Fee Fee Fee Paid Fee Description 1254 1 450 Fee Fee 2254 725 Extension for reply within fourth month 2255 985 Extension for reply within fifth month 1255 1.970 1001 750 2001 375 Utility filing fee 750 2002 165 Design filing fee 1401 320 2401 160 Notice of Appeal 1002 220 1003 520 2002 260 Plant filing for 1402 320 2402 160 Filing a brief in support of an appeal 1403 280 2403 140 Request for oral hearing

1004 750 2004 375 Reissue filing fee 1451 1.510 1451 1.510 Petition to institute a public use proceeding 2005 80 Provisional filing fee 1005 160 1452 110 2452 55 Petition to revive - unavoidable SUBTOTAL (1) (\$) 750 1453 1,300 2453 650 Petition to revive - unintentional Y AND REISSUE 2. EXTRA CLAIM FEES FOR UTILIT 1501 1 300 2501 650 Utility issue fee (or reissue) 1502 470 2502 235 Design issue fee pelow Total Claims 1503 630 2503 315 Plant issue fee independent 1460 130 1460 130 Petitions to the Commissioner Claims
Multiple Dependent 1807 50 1807 50 Processing fee under 37 CFR 1.17(q) 1806 180 Submission of information Disclosure Stmt 1806 180 Fee Fee Fee Description 8021 40 Recording each patent assignment per 8021 40 Code (S) 2202 9 Claims in excess of 20 1202 18 1809 750 2809 375 Filing a submission after final rejection (37 CFR 1.129(a)) 2201 42 Independent claims in excess of 3 1201 84

1810 750

1801 750 2801

1802 900 1802

2810 375 For each additional invention to be examined (37 CFR 1.129(b))

of a design application

375 Request for Continued Examination (RCE)

900 Request for expedited examination

2203 140 Multiple dependent claim, if not paid

\* Reissue claims in excess ot 20

and over original patent

2204 42 Reissue independent claims over original patent

1203 280

1204 84

1205 18

WARNING-Information n this frm may bec m public. Cr dit card infrmati n should n the included n this form. Pr vide cr dit card infrmati n and auth rizati n n PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Conditionality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to lake 12 timulates complete, including gathering, prepring, and authoriting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form andors orgagestions for reducing this turders, should be sent to the Other Information (F.U.S. Patient and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, Washington, DC 20231.